See more : Liberty Shoes Ltd. (LIBERTSHOE.NS) Income Statement Analysis – Financial Results
Complete financial analysis of KPC Pharmaceuticals, Inc. (600422.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of KPC Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Advanced Powerline Technologies, Inc. (APWL) Income Statement Analysis – Financial Results
- Scholar Education Group (1769.HK) Income Statement Analysis – Financial Results
- Victoria Oil & Gas Plc (VCOGF) Income Statement Analysis – Financial Results
- Clover Biopharmaceuticals, Ltd. (2197.HK) Income Statement Analysis – Financial Results
- Weichai Power Co., Ltd. (WI4.VI) Income Statement Analysis – Financial Results
KPC Pharmaceuticals, Inc. (600422.SS)
About KPC Pharmaceuticals, Inc.
KPC Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People's Republic of China and internationally. It offers artemether, panax notoginseng, and gastrodine series drugs, as well as Chinese medicines and ethnic drugs under the Luotai, Tianxuanqing, Artemedine, Artem, and Arco brand names for treating cardio-cerebral-vascular and nervous system diseases, as well as malaria. The company also provides Dai medicines; antibiotics, chemical medicinal raw materials, chemical pharmaceutical preparations, traditional Chinese medicinal materials, biological products, biochemical drugs, and health foods; Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, and Ribavirin spray products; glycyrrhizic acid; and GLP-1, a long-acting hypoglycemic drug. It markets artemisinin antimalarials, generic drugs, and medical apparatus. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals, Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.70B | 8.28B | 8.25B | 7.72B | 8.12B | 7.10B | 5.85B | 5.10B | 4.92B | 4.12B | 3.58B | 3.02B | 2.43B | 1.82B | 1.43B | 1.31B | 1.29B | 1.15B | 1.21B | 673.67M | 665.34M | 504.86M | 488.24M | 511.36M | 454.25M | 395.15M | 272.21M |
| Cost of Revenue | 4.29B | 4.84B | 4.84B | 4.33B | 4.17B | 3.56B | 3.22B | 3.13B | 3.22B | 2.89B | 2.54B | 2.06B | 1.71B | 1.23B | 929.15M | 857.80M | 857.19M | 828.15M | 932.00M | 296.85M | 296.95M | 279.59M | 285.63M | 316.51M | 300.13M | 239.48M | 172.72M |
| Gross Profit | 3.41B | 3.44B | 3.41B | 3.38B | 3.95B | 3.54B | 2.63B | 1.97B | 1.70B | 1.23B | 1.04B | 957.76M | 721.33M | 588.99M | 505.76M | 453.13M | 433.07M | 318.40M | 275.63M | 376.83M | 368.39M | 225.27M | 202.61M | 194.85M | 154.12M | 155.68M | 99.49M |
| Gross Profit Ratio | 44.26% | 41.52% | 41.30% | 43.84% | 48.68% | 49.89% | 44.95% | 38.66% | 34.50% | 29.94% | 29.15% | 31.76% | 29.64% | 32.41% | 35.25% | 34.57% | 33.56% | 27.77% | 22.82% | 55.94% | 55.37% | 44.62% | 41.50% | 38.10% | 33.93% | 39.40% | 36.55% |
| Research & Development | 71.26M | 69.65M | 100.52M | 128.45M | 83.51M | 77.11M | 63.19M | 88.47M | 44.03M | 15.28M | 18.82M | 17.00M | 8.86M | 8.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 76.79M | 82.59M | 118.26M | 120.17M | 102.27M | 99.38M | 89.20M | 73.82M | 67.75M | 68.10M | 66.76M | 47.59M | 42.59M | 35.01M | 97.18M | 97.46M | 94.91M | 85.32M | 112.19M | 73.46M | 91.45M | 58.31M | 62.68M | 50.04M | 43.81M | 51.11M | 36.66M |
| Selling & Marketing | 2.07B | 2.43B | 2.37B | 2.35B | 2.98B | 2.66B | 1.81B | 1.18B | 881.59M | 652.54M | 542.14M | 541.39M | 394.49M | 338.38M | 293.76M | 275.21M | 260.09M | 195.10M | 239.60M | 193.09M | 180.33M | 112.01M | 95.14M | 84.89M | 71.61M | 61.71M | 40.57M |
| SG&A | 2.79B | 2.52B | 2.49B | 2.47B | 3.08B | 2.76B | 1.90B | 1.26B | 949.34M | 720.64M | 608.90M | 588.98M | 437.08M | 373.39M | 390.94M | 372.67M | 355.01M | 280.43M | 351.79M | 266.55M | 271.77M | 170.32M | 157.82M | 134.93M | 115.43M | 112.81M | 77.23M |
| Other Expenses | -21.15M | 239.23M | 240.39M | 238.81M | 228.60M | -2.68M | -3.98M | 57.43M | 41.08M | 26.57M | 17.95M | 21.87M | 12.61M | 6.16M | 5.32M | 4.69M | 5.32M | -2.41M | -3.01M | 3.00M | 552.44K | 4.89M | 2.84M | 5.50M | 7.26M | 4.92M | 7.61M |
| Operating Expenses | 2.84B | 2.82B | 2.83B | 2.84B | 3.39B | 3.11B | 2.19B | 1.57B | 1.21B | 894.03M | 754.79M | 721.28M | 542.53M | 459.41M | 399.06M | 380.16M | 361.23M | 284.35M | 356.22M | 271.66M | 276.71M | 172.97M | 160.45M | 137.10M | 117.62M | 114.20M | 78.18M |
| Cost & Expenses | 7.13B | 7.67B | 7.68B | 7.17B | 7.56B | 6.67B | 5.41B | 4.69B | 4.43B | 3.78B | 3.29B | 2.78B | 2.26B | 1.69B | 1.33B | 1.24B | 1.22B | 1.11B | 1.29B | 568.51M | 573.66M | 452.56M | 446.09M | 453.61M | 417.74M | 353.68M | 250.90M |
| Interest Income | 9.26M | 6.07M | 5.45M | 7.70M | 5.53M | 8.91M | 3.62M | 5.54M | 6.82M | 3.83M | 5.09M | 3.95M | 2.16M | 1.78M | 1.09M | 1.45M | 1.13M | 3.01M | 1.99M | 2.37M | 3.39M | 4.95M | 3.37M | 1.00M | -0.71 | -0.29 | -0.19 |
| Interest Expense | 19.31M | 40.73M | 33.59M | 29.16M | 40.41M | 41.50M | 23.59M | 20.03M | 19.59M | 11.22M | 20.02M | 11.93M | 10.79M | 8.15M | 11.29M | 19.58M | 22.37M | 17.55M | 11.34M | 7.31M | 4.14M | 959.80K | 1.80M | 8.64M | 6.91M | 8.23M | 5.33M |
| Depreciation & Amortization | 213.63M | 243.61M | 197.53M | 172.03M | 136.00M | 108.66M | 98.45M | 84.67M | 76.85M | 55.87M | 45.13M | 43.21M | 36.23M | 36.38M | 36.01M | 33.87M | 31.38M | 30.85M | 28.76M | 22.23M | 19.33M | 13.67M | 16.25M | 15.24M | 11.97M | 9.44M | 5.08M |
| EBITDA | 801.82M | 726.82M | 870.95M | 757.05M | 727.36M | 558.76M | 548.02M | 598.38M | 610.56M | 464.97M | 348.78M | 297.92M | 223.01M | 161.90M | 127.11M | 96.42M | 89.93M | 65.09M | -46.89M | 115.32M | 115.29M | 79.21M | 67.71M | 82.12M | 48.47M | 41.47M | 21.31M |
| EBITDA Ratio | 10.41% | 9.94% | 10.93% | 9.12% | 9.04% | 8.08% | 9.35% | 11.54% | 12.55% | 10.77% | 9.94% | 10.00% | 9.41% | 9.56% | 10.36% | 8.70% | 8.69% | 5.53% | -4.00% | 21.32% | 17.33% | 15.69% | 13.87% | 15.61% | 10.86% | 10.67% | 7.83% |
| Operating Income | 568.50M | 497.15M | 634.05M | 540.83M | 539.80M | 419.81M | 411.91M | 424.31M | 465.42M | 339.54M | 266.05M | 222.17M | 163.19M | 111.21M | 74.60M | 38.55M | 31.09M | 18.22M | -84.09M | 113.28M | 93.68M | 61.46M | 46.73M | 51.94M | 29.77M | 32.71M | 16.23M |
| Operating Income Ratio | 7.38% | 6.00% | 7.68% | 7.01% | 6.65% | 5.91% | 7.04% | 8.32% | 9.47% | 8.24% | 7.42% | 7.37% | 6.70% | 6.12% | 5.20% | 2.94% | 2.41% | 1.59% | -6.96% | 16.81% | 14.08% | 12.17% | 9.57% | 10.16% | 6.55% | 8.28% | 5.96% |
| Total Other Income/Expenses | -4.88M | -19.86M | -2.76M | -343.62K | 4.63M | -2.68M | -4.00M | 57.21M | 40.50M | 36.83M | 17.58M | 19.79M | 11.96M | 6.15M | -5.30M | -30.00M | -35.66M | -3.25M | -4.27M | 830.49K | -1.86M | 3.13M | 2.94M | 5.07M | 5.87M | 4.78M | 7.37M |
| Income Before Tax | 563.62M | 477.29M | 631.29M | 540.49M | 544.43M | 417.14M | 407.93M | 480.93M | 505.91M | 365.95M | 283.63M | 241.97M | 175.15M | 117.36M | 79.64M | 42.98M | 36.18M | 14.98M | -88.36M | 114.11M | 91.82M | 64.58M | 49.67M | 57.01M | 35.64M | 37.49M | 23.60M |
| Income Before Tax Ratio | 7.32% | 5.76% | 7.65% | 7.00% | 6.70% | 5.87% | 6.97% | 9.43% | 10.29% | 8.88% | 7.91% | 8.02% | 7.20% | 6.46% | 5.55% | 3.28% | 2.80% | 1.31% | -7.32% | 16.94% | 13.80% | 12.79% | 10.17% | 11.15% | 7.85% | 9.49% | 8.67% |
| Income Tax Expense | 109.48M | 91.83M | 118.07M | 78.30M | 76.68M | 75.45M | 72.64M | 71.41M | 74.60M | 58.26M | 47.98M | 40.79M | 29.69M | 18.69M | 12.68M | 6.77M | 5.23M | 7.50M | 12.47M | 16.64M | 11.08M | 11.49M | 4.64M | 7.56M | 4.01M | 4.22M | 3.08M |
| Net Income | 444.68M | 383.18M | 507.67M | 456.86M | 454.31M | 335.54M | 330.10M | 407.26M | 420.85M | 292.24M | 231.62M | 181.75M | 130.12M | 85.58M | 58.32M | 32.12M | 29.07M | 17.83M | -44.57M | 91.78M | 70.39M | 44.59M | 38.32M | 35.18M | 23.90M | 24.08M | 11.02M |
| Net Income Ratio | 5.77% | 4.63% | 6.15% | 5.92% | 5.59% | 4.72% | 5.64% | 7.98% | 8.56% | 7.09% | 6.46% | 6.03% | 5.35% | 4.71% | 4.06% | 2.45% | 2.25% | 1.56% | -3.69% | 13.62% | 10.58% | 8.83% | 7.85% | 6.88% | 5.26% | 6.09% | 4.05% |
| EPS | 0.59 | 0.51 | 0.67 | 0.60 | 0.60 | 0.44 | 0.42 | 0.52 | 0.53 | 0.37 | 0.36 | 0.29 | 0.21 | 0.14 | 0.09 | 0.05 | 0.05 | 0.00 | -0.07 | 0.08 | 0.09 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.02 |
| EPS Diluted | 0.59 | 0.51 | 0.67 | 0.60 | 0.60 | 0.44 | 0.42 | 0.52 | 0.53 | 0.37 | 0.36 | 0.29 | 0.21 | 0.14 | 0.09 | 0.05 | 0.05 | 0.00 | -0.07 | 0.08 | 0.09 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.02 |
| Weighted Avg Shares Out | 753.69M | 751.34M | 758.26M | 759.15M | 761.37M | 768.52M | 785.76M | 788.64M | 788.70M | 788.74M | 650.81M | 628.35M | 628.31M | 628.33M | 628.48M | 628.53M | 628.52M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M |
| Weighted Avg Shares Out (Dil) | 753.69M | 751.34M | 758.26M | 759.15M | 761.63M | 768.52M | 785.76M | 788.64M | 788.70M | 788.74M | 650.81M | 628.35M | 628.31M | 628.33M | 628.48M | 628.53M | 628.52M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M | 628.23M |
Source: https://incomestatements.info
Category: Stock Reports